A phase III study of controlled-release metadoxine in children with attention-deficit hyperactivity disorder (ADHD).
Phase of Trial: Phase III
Latest Information Update: 15 Nov 2017
At a glance
- Drugs Metadoxine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Registrational; Therapeutic Use
- 15 Nov 2017 According to an Arcturus Therapeutics media release, Alcobra merged with Arcturus Therapeutics and the combined company is named as Arcturus Therapeutics
- 30 Aug 2016 According to Alcobra media release, this study is expected to start in the fourth quarter of 2016.
- 06 Aug 2013 This trial is expected to start later in 2013, according to an Alcobra media release.